agenT-797 + Approved ICIs
Phase 1Completed 0 watching 0 views this week๐ค Quiet
25
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tumor, Solid
Conditions
Tumor, Solid
Trial Timeline
Jan 28, 2022 โ Jan 2, 2024
NCT ID
NCT05108623About agenT-797 + Approved ICIs
agenT-797 + Approved ICIs is a phase 1 stage product being developed by MiNK Therapeutics for Tumor, Solid. The current trial status is completed. This product is registered under clinical trial identifier NCT05108623. Target conditions include Tumor, Solid.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05108623 | Phase 1 | Completed |
Competing Products
20 competing products in Tumor, Solid